Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong
· Delayed Price · Currency is HKD 5.46
-0.02 (-0.36%)
Apr 29, 2026, 4:08 PM HKT
Sino Biopharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | - | 3,500 | 2,332 | 2,544 | 14,608 | Upgrade
|
| Depreciation & Amortization | - | 1,175 | 1,004 | 967.54 | 922.74 | Upgrade
|
| Other Amortization | - | 145.7 | 70.05 | 79.45 | 129.82 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -40.9 | -62.69 | -3.47 | 4.28 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 305.43 | - | 19.4 | 492.1 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | 1,483 | 13.72 | 449.08 | 420.04 | Upgrade
|
| Loss (Gain) on Equity Investments | - | 118.3 | 525.71 | 152.98 | -13,631 | Upgrade
|
| Stock-Based Compensation | - | 53.72 | 18.12 | 29.72 | - | Upgrade
|
| Provision & Write-off of Bad Debts | - | 12.79 | -12.26 | 3.93 | 1.62 | Upgrade
|
| Other Operating Activities | - | -257.16 | 2,316 | 1,655 | 2,757 | Upgrade
|
| Change in Accounts Receivable | - | -413.99 | -816.03 | -421.66 | -1,308 | Upgrade
|
| Change in Inventory | - | -273.06 | 135.32 | -391.1 | -57.48 | Upgrade
|
| Change in Accounts Payable | - | 130.11 | 284.3 | -55.8 | -257.84 | Upgrade
|
| Change in Unearned Revenue | - | 29.26 | -142.32 | 74.62 | 66.25 | Upgrade
|
| Change in Other Net Operating Assets | - | 714.15 | 108.21 | 598.34 | 1,218 | Upgrade
|
| Operating Cash Flow | - | 6,615 | 6,066 | 6,265 | 5,366 | Upgrade
|
| Operating Cash Flow Growth | - | 9.06% | -3.18% | 16.75% | 0.77% | Upgrade
|
| Capital Expenditures | - | -960.1 | -1,068 | -1,243 | -1,714 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 70.85 | 100.99 | 27.89 | 132.2 | Upgrade
|
| Cash Acquisitions | - | 2.66 | -1,157 | - | -798.75 | Upgrade
|
| Divestitures | - | 1,404 | 413.81 | -146.17 | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | -434.06 | -406.78 | -302.94 | -152.92 | Upgrade
|
| Investment in Securities | - | -3,819 | 568.91 | -3,703 | -4,391 | Upgrade
|
| Other Investing Activities | - | 2,026 | 790.43 | 1,297 | 4,408 | Upgrade
|
| Investing Cash Flow | - | -1,709 | -756.98 | -4,071 | -2,516 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 136.13 | Upgrade
|
| Long-Term Debt Issued | - | 11,696 | 12,194 | 9,753 | 1,270 | Upgrade
|
| Total Debt Issued | - | 11,696 | 12,194 | 9,753 | 1,406 | Upgrade
|
| Long-Term Debt Repaid | - | -14,475 | -13,948 | -8,790 | -2,908 | Upgrade
|
| Net Debt Issued (Repaid) | - | -2,779 | -1,754 | 962.99 | -1,501 | Upgrade
|
| Repurchase of Common Stock | - | -1,252 | -396.39 | -867.61 | -332.93 | Upgrade
|
| Common Dividends Paid | - | -1,846 | -632.67 | -1,268 | -938.49 | Upgrade
|
| Other Financing Activities | - | -437.24 | -3,766 | -2,014 | -452.37 | Upgrade
|
| Financing Cash Flow | - | -6,315 | -6,549 | -3,186 | -3,225 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 135.52 | 90.52 | 47.32 | -649.71 | Upgrade
|
| Net Cash Flow | - | -1,274 | -1,150 | -944.73 | -1,025 | Upgrade
|
| Free Cash Flow | - | 5,655 | 4,998 | 5,022 | 3,652 | Upgrade
|
| Free Cash Flow Growth | - | 13.15% | -0.48% | 37.50% | -6.38% | Upgrade
|
| Free Cash Flow Margin | - | 19.59% | 19.08% | 19.30% | 13.60% | Upgrade
|
| Free Cash Flow Per Share | - | 0.31 | 0.27 | 0.26 | 0.19 | Upgrade
|
| Cash Interest Paid | - | 287.25 | 480.83 | 339.52 | 179.62 | Upgrade
|
| Cash Income Tax Paid | - | 1,001 | 746.57 | 892.09 | 726.72 | Upgrade
|
| Levered Free Cash Flow | - | 3,905 | 3,006 | 2,991 | -196.74 | Upgrade
|
| Unlevered Free Cash Flow | - | 4,089 | 3,316 | 3,259 | -3.85 | Upgrade
|
| Change in Working Capital | - | 186.47 | -430.51 | -195.6 | -339.14 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.